Galvez v. Frields

107 Cal. Rptr. 2d 50, 88 Cal. App. 4th 1410, 2001 Daily Journal DAR 4769, 2001 Cal. Daily Op. Serv. 3907, 2001 Cal. App. LEXIS 355
CourtCalifornia Court of Appeal
DecidedMay 15, 2001
DocketB125543
StatusPublished
Cited by26 cases

This text of 107 Cal. Rptr. 2d 50 (Galvez v. Frields) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Galvez v. Frields, 107 Cal. Rptr. 2d 50, 88 Cal. App. 4th 1410, 2001 Daily Journal DAR 4769, 2001 Cal. Daily Op. Serv. 3907, 2001 Cal. App. LEXIS 355 (Cal. Ct. App. 2001).

Opinion

*1413 Opinion

VOGEL (C. S.), P. J.

Introduction

This is a medical malpractice case in which Nathaniel Galvez sues defendant Michael Frields, M.D., for wrongful life, contending that Frields failed to make reasonable efforts to ensure Nathaniel’s mother, Michelle Sepulveda, was given a blood test to detect the presence of the neural tube defect from which Nathaniel suffers. Plaintiff filed this action against Frields and several other defendants. 1 Following a trial during which the trial court refused to give a jury instruction on negligence per se (BAJI No. 3.45), the jury found that Frields was not negligent in his care of Sepulveda. Nathaniel appeals and asserts as the sole claimed error the trial court’s refusal to give the negligence per se instruction. We conclude that the court erred in refusing to give the proffered instruction. Such error was clearly prejudicial, and we therefore reverse and remand for a new trial.

Factual and Procedural Background

“Since the only contention on appeal related to a jury instruction, ‘[i]n assessing an instruction’s prejudicial impact, we cannot use the view of the evidence and inferences most favorable to the [prevailing party], [Citations.] Instead, we must assume the jury might have believed [appellant’s] evidence and, if properly instructed, might have decided in [appellant’s] favor. [Citations.]’ (Shell Oil Co. v. Winterthur Swiss Ins. Co. (1993) 12 Cal.App.4th 715, 773 [15 Cal.Rptr.2d 815].) Accordingly, we state the facts most favorably to the party appealing the instructional error alleged, in accordance with the customary rule of appellate review. (Sills v. Los Angeles Transit Lines (1953) 40 Cal.2d 630, 633 [255 P.2d 795].)” (Logacz v. Limansky (1999) 71 Cal.App.4th 1149, 1152, fn. 2 [84 Cal.Rptr.2d 257].)

Alpha-fetoprotein Testing

Title 17 of the California Code of Regulations, section 6527, enacted in April 1986 pursuant to former section 289.7 of the Health and Safety Code (now Health & Saf. Code, § 125070), requires clinicians who provide prenatal care to advise all pregnant women in their care of the availability of *1414 the alpha-fetoprotein (AFP) test, which screens for neural tube defects in the fetus. 2 Section 6527 provides in relevant part as follows:

“(a) Clinicians shall provide or cause to be provided to all pregnant women in their care before the 140th day of gestation, or before the 126th day from conception, as estimated by medical history or clinical testing, information regarding the use and availability of prenatal screening for birth defects of the fetus. This information shall be in a format to be provided or approved by the Department and shall be given at the first prenatal visit and discussed with each pregnant woman.
“(b) The provisions of subsection (a) shall not apply if the pregnant woman has completed more than 140 days of gestation or 126 days post conception, as estimated by medical history or clinical testing, and this fact is entered in the medical record.
“(c) Clinicians shall cause to be provided to all pregnant women who, after being provided with the information pursuant to subsection (a), voluntarily request prenatal screening for birth defects of the fetus, the opportunity, the circumstances of which are to be documented in the medical record, to read and sign an informed consent document in a format provided or approved by the Department.
“(d) If the pregnant woman consents to testing, the clinician shall arrange for prenatal screening directly or by referral to another clinician by:
“(1) Fully and accurately completing all required specimen collection forms provided by the Department for this purpose;
“(2) Collecting or arranging for the collection of an initial specimen following state directions for collection provided;
“(3) As soon as possible, but within 24 hours of collection, place or cause to be placed all initial and repeat specimens in the channel of transmittal to the designated Expanded AFP prenatal birth defects screening laboratory. [¶] ... [¶]
“(i) Recognizing the strict gestational and time limits wherein prenatal detection of birth defects of the fetus is feasible, clinicians shall make *1415 every reasonable effort to schedule screening and differential diagnostic tests and procedures appropriately with respect to the gestational dates of the pregnant woman. . . .” (Boldface added.)

George Cunningham, M.D., chief of the Genetic Disease Branch of the California Department of Health Services (which administers the statewide program to screen for birth defects), participated in drafting the laws and regulations governing AFP testing. He testified at trial that neural tube defects are “a serious and common birth defect so it’s to the individual family’s interest and also to the State’s interest to identify these defects prenatally so that if the woman chooses to terminate the pregnancy she has an opportunity to do that.” A large majority of women who are told of the existence of a fetal neural tube defect elect to terminate their pregnancies.

AFP testing, which must be done between 15 and 19 completed weeks of pregnancy (or stated otherwise, between the beginning of the 16th week and the 20th week), involves drawing blood from the pregnant woman into a test tube provided by the state. The process of drawing the blood is no different from any other type of test requiring that blood be drawn. The blood sample does not have to be prepared for shipment; it is placed in the packaging provided by the state with a prepaid mailing label. The sample can be refrigerated if it cannot be mailed promptly. The time requirements imposed by the regulation are not in order to get an accurate result, rather they allow for follow-up diagnostic testing to be done while termination of the pregnancy is still feasible. The test results have to get back to the doctor; if the test is positive, the woman has to make an appointment at a prenatal center; an ultrasound is done; if amniocentesis (testing of the amniotic fluid) is done it takes two weeks to grow the cells and do the chromosome studies to confirm or deny the presence of a defect. 3

Cunningham said that the regulations require doctors to make reasonable efforts to make sure the woman is tested within the window. He acknowledged that there are different styles of practice, and that the Department of Health Services leaves the details as to how to do it up to individual practitioners. “[B]ut we expect they would make reasonable efforts if the woman says she wants to be tested to make sure some time in that period they got blood drawn.”

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Soto v. Walmart CA5
California Court of Appeal, 2025
Daniel C. v. White Memorial Medical Center
California Court of Appeal, 2022
Wilson v. Pan Norcal, LLC
E.D. California, 2022
G.M. v. Adams CA2/1
California Court of Appeal, 2022
DeLeon v. Hot Doggers Tours CA4/1
California Court of Appeal, 2022
Zuelke v. City of Modesto CA5
California Court of Appeal, 2021
Klemke v. ISEC, Inc. CA4/1
California Court of Appeal, 2014
Vollaro v. Lispi
224 Cal. App. 4th 93 (California Court of Appeal, 2014)
Hegedus v. Behavioral Health Services CA2/3
California Court of Appeal, 2013
Spriesterbach v. Holland
215 Cal. App. 4th 255 (California Court of Appeal, 2013)
Sanchez v. United States
803 F. Supp. 2d 1066 (C.D. California, 2011)
Das v. Bank of America, N.A.
186 Cal. App. 4th 727 (California Court of Appeal, 2010)
Deutsch v. Masonic Homes of California, Inc.
164 Cal. App. 4th 748 (California Court of Appeal, 2008)
Barragan v. Lopez
68 Cal. Rptr. 3d 73 (California Court of Appeal, 2007)
Ermoian v. Desert Hospital
61 Cal. Rptr. 3d 754 (California Court of Appeal, 2007)
Quiroz v. Seventh Avenue Center
45 Cal. Rptr. 3d 222 (California Court of Appeal, 2006)
Munoz v. City of Union City
16 Cal. Rptr. 3d 521 (California Court of Appeal, 2004)
Viner v. Sweet
12 Cal. Rptr. 3d 533 (California Court of Appeal, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
107 Cal. Rptr. 2d 50, 88 Cal. App. 4th 1410, 2001 Daily Journal DAR 4769, 2001 Cal. Daily Op. Serv. 3907, 2001 Cal. App. LEXIS 355, Counsel Stack Legal Research, https://law.counselstack.com/opinion/galvez-v-frields-calctapp-2001.